title: Short communication: effects of omega-3 fatty acids on triglycerides and high-density lipoprotein subprofiles in HIV-infected persons with hypertriglyceridemia.
abstract: Hypertriglyceridemia and low high-density lipoprotein (HDL)-cholesterol (HDL-C) may contribute to a presumed accelerated risk for cardiovascular disease in HIV-infected individuals. We evaluated the effect of omega-3 fatty acid treatment on triglycerides, low-density lipoprotein (LDL)-C, HDL-C, and HDL subpopulations. Forty-one HIV-seropositive subjects with hypertriglyceridemia (≥150 mg/dl) on active antiretroviral therapy were enrolled in this placebo-controlled, double-blind, randomized, crossover trial comparing the effects of omega-3 fatty acid treatment (1.9 g EPA and 1.5 g DHA) on triglycerides, LDL-C, HDL-C, and HDL subpopulations. An independent sample t-test was used to assess the study start to posttreatment change for all components. After omega-3 fatty acid treatment, triglyceride levels decreased 63.2±86.9 mg/dl (p<0.001). No significant changes in total cholesterol, LDL-C, or HDL-C were found. Within HDL subpopulations, significant changes were seen in the most atheroprotective HDL particles, α-1, which increased by 2.5±5.6 mg/dl (p<0.05), and preα-1, which increased by 0.6±1.0 mg/dl (p<0.001). Preα-3, a presumably atherogenic HDL particle, decreased by 0.5±0.9 mg/dl (p<0.01). Omega-3 fatty acid treatment significantly lowered triglyceride levels in HIV-positive patients with moderate hypertriglyceridemia. While no study-wide improvements in LDL-C or HDL-C were detected, the HDL subpopulation profile changed in a beneficial way suggesting more cardioprotection after treatment.
authors.affiliation: 1 Tufts Medical Center , Division of Geographic Medicine and Infectious Diseases, Boston, Massachusetts.
authors.forename: Anu
authors.initials: A
authors.lastname: Paranandi
authors.forename: Bela F
authors.initials: BF
authors.lastname: Asztalos
authors.forename: Alexandra
authors.initials: A
authors.lastname: Mangili
authors.forename: Jefferey
authors.initials: J
authors.lastname: Kuvin
authors.forename: Jul
authors.initials: J
authors.lastname: Gerrior
authors.forename: Heidi
authors.initials: H
authors.lastname: Sheehan
authors.forename: Sally C
authors.initials: SC
authors.lastname: Skinner
authors.forename: Alice M
authors.initials: AM
authors.lastname: Tang
authors.forename: Christine A
authors.initials: CA
authors.lastname: Wanke
mesh_terms: D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D018592:Cross-Over Studies; D004311:Double-Blind Method; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage*; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D015228:Hypertriglyceridemia / Q000188:drug therapy*; D008075:Lipoproteins, HDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010919:Placebos / Q000008:administration & dosage; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood*
chemical_list: D044966:Anti-Retroviral Agents; D015525:Fatty Acids, Omega-3; D008075:Lipoproteins, HDL; D010919:Placebos; D014280:Triglycerides